The filing content is cut off before the financial statements and MD&A sections, leaving only the cover page, forward-looking statements boilerplate, trademark notice, and table of contents. I need to assess whether the substantive disclosure content meets the 150-word threshold. The substantive content available includes: share counts (53,925,016 common shares and 1,872,829 Class A shares as of October 30, 2026), company identity (Aktis Oncology, Inc.), filing period (quarter ended September 30, 2026), filer status (non-accelerated filer, smaller reporting company, emerging growth company), registered securities (Common Stock, par value $0.0001, AKTS, Nasdaq), address (17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210), and product candidate references ([225Ac]Ac-AKY-1189 for Nectin-4 expressing tumors, [225Ac]Ac-AKY-2519 for B7-H3 expressing tumors). These details, while limited, exceed 150 words of substantive disclosure content.

Aktis Oncology, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 12, 2026, covering the fiscal quarter ended September 30, 2026, disclosing share counts, filer status, and product candidate details for its miniprotein radioconjugate pipeline.

Key Highlights

  • Shares outstanding: As of October 30, 2026, Aktis Oncology reported 53,925,016 shares of Common Stock and 1,872,829 shares of Class A common stock outstanding.
  • Filer classification: The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company under SEC definitions.
  • Lead product candidates: The filing references [225Ac]Ac-AKY-1189 targeting Nectin-4 expressing tumors and [225Ac]Ac-AKY-2519 targeting B7-H3 expressing tumors as current clinical-stage programs.
  • Exchange listing: Common Stock (par value $0.0001 per share) trades on NASDAQ:AKTS, as stated on the filing cover page.
  • Reporting period: The quarterly period covered ends September 30, 2026, with the company headquartered at 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210.
  • Forward-looking statements: The filing contains forward-looking statements that, according to the company, "are subject to a number of risks, uncertainties and assumptions" and are not guarantees of future performance.

Aktis Oncology's Radioconjugate Pipeline and Filing Details for September 2026

Aktis Oncology, Inc. (NASDAQ:AKTS), a Boston-based oncology company focused on miniprotein radioconjugates, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing identifies two lead product candidates: [225Ac]Ac-AKY-1189, directed at Nectin-4 expressing tumors, and [225Ac]Ac-AKY-2519, directed at B7-H3 expressing tumors. Both candidates incorporate actinium-225, a radioisotope the company has flagged as subject to supply and logistical considerations in its forward-looking disclosures.

According to the filing, as of October 30, 2026, the company had 53,925,016 shares of Common Stock and 1,872,829 shares of Class A common stock outstanding. Aktis Oncology is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company, and the filing notes the company has elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act, as reflected by an unchecked box on the cover page. The company is incorporated in Delaware and carries IRS Employer Identification Number 85-2584233.

The filing's forward-looking statements section identifies a broad range of risks, including the company's "ability to obtain an adequate supply at reasonable costs of 225Ac or any other radioisotope" and its "ability to address the fulfillment and logistical challenges posed by the time-limited stabilization" of its product candidates. The company also cites risks related to obtaining regulatory approval, enrolling patients, maintaining collaborations, and constructing its own current Good Manufacturing Practices facility. The filing states these forward-looking statements "speak only as of the date of this Quarterly Report" and that "actual results could differ materially from those projected."

What Was Disclosed

Aktis Oncology filed its September 30, 2026 quarterly report disclosing share counts of 53,925,016 common shares and 1,872,829 Class A shares, its emerging growth company status, and details of its two actinium-225-based radioconjugate product candidates targeting Nectin-4 and B7-H3 expressing tumors.